iSpecimen Inc.
ISPC Nasdaq Services-Commercial Physical & Biological Research 金融 FY2020–FY2025
最新收盘价 · 2026年10月23日
$0.82
1.9%iSpecimen Inc. 的业务
暂无业务介绍。
- 法定名称
- iSpecimen Inc.
- 财年结束日
- 2025年12月31日
- 最新年报
- 10-K · 2026年4月1日
- 登记号 · CIK
- 0001213900-26-038607
0001558569
营收与利润率
iSpecimen Inc. 在 2025 财年 营收为 $1.9M,同比下降 79.2%。
净利润与每股收益
亏损期间以红色显示。
资本回报率
税后营业利润占投入业务资金(债务加股东权益减现金)的比例。
现金流
2025 财年 的自由现金流为 −$4.2M,占营收的 −219.9%。 经营现金流减资本支出。
股息、回购与股数
iSpecimen Inc. 在 2025 财年 向股东返还 —。 稀释股数增加 547.4%。
资产负债表
现金、债务以及显示 iSpecimen Inc. 承担债务能力的指标。
| 财年末 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| 现金及短期投资 | $27.7M | $15.3M | $5.0M | $1.9M | $6.9M |
| 债务(含融资租赁) | $3.4M | — | — | — | — |
| 债务 / 股东权益 | 0.1x | — | — | — | — |
| 利息保障倍数 | −2.8x | −42.6x | −698.1x | −73.2x | −4,725.2x |
| 流动比率 | 13.2x | 4.6x | 1.4x | 0.6x | 1.1x |
| 速动比率 | 13.2x | 4.6x | 1.4x | 0.6x | 1.1x |
| 总资产 | $35.7M | $24.6M | $15.8M | $9.4M | $9.5M |
| 总负债 | $5.9M | $4.3M | $6.1M | $6.0M | $6.4M |
| 股东权益 | $29.8M | $20.3M | $9.7M | $3.3M | $3.1M |
| 净债务 (− = 净现金) | −$24.3M | — | — | — | — |
内部人交易
高管、董事和持股超过 10% 的股东在公开市场的买卖,数据来自 Form 4 申报。“计划”表示依据事先制定的 Rule 10b5-1 计划进行的交易。
买入(12 个月)
$0.0M
0 名内部人士
卖出(12 个月)
$0.0M
0 名内部人士
卖出中按计划执行的比例
—
$0.0M
过去 12 个月没有公开市场的内部人交易。
Piotroski F 分数
关于盈利能力、融资和效率的九项通过/未通过测试。8–9 为强,0–2 为弱。
| 测试项 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| 净利润为正 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| 经营现金流为正 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| 资产回报率上升 | — | ✓ | ✕ | ✕ | ✕ | ✓ |
| 经营现金流高于净利润 | ✓ | ✕ | ✓ | ✓ | ✓ | ✓ |
| 债务相对资产下降 | — | — | — | — | — | — |
| 流动比率上升 | — | ✓ | ✕ | ✕ | ✕ | ✓ |
| 股数未增加 | — | ✕ | ✕ | ✓ | ✕ | ✕ |
| 毛利率上升 | — | ✕ | ✓ | ✕ | ✕ | ✕ |
| 营收相对资产上升 | — | ✕ | ✓ | ✓ | ✓ | ✕ |
| F 分数 | — / 3 | 2 / 8 | 3 / 8 | 3 / 8 | 2 / 8 | 3 / 8 |
| 应计比率 | −70.3% | 8.1% | −14.7% | −26.2% | −33.6% | −66.2% |
| Altman Z'' | −38.86 | 6.28 | −0.12 | −14.39 | −35.16 | −33.49 |
6 年数据
金额单位为 USD。将鼠标悬停在指标名称上可查看定义。
| 财年 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| 利润表 | ||||||
| 营收 | $8.2M | $11.1M | $10.4M | $9.9M | $9.3M | $1.9M |
| 毛利 | $4.6M | $5.9M | $5.6M | $5.2M | $4.2M | $0.2M |
| 研发支出 | $0.3M | $0.9M | $1.5M | $1.6M | $1.5M | — |
| 营业利润 | −$2.4M | −$5.9M | −$10.2M | −$11.2M | −$12.7M | −$9.0M |
| 利息支出 | $2.1M | $2.1M | $0.2M | $0.0M | $0.2M | $0.0M |
| 所得税 | $0.0M | $0.0M | $0.0M | — | — | — |
| 净利润 | −$4.7M | −$9.0M | −$10.2M | −$11.1M | −$12.5M | −$10.5M |
| 稀释每股收益 | −$4.97 | −$2.09 | −$1.16 | −$24.55 | −$17.58 | −$2.28 |
| 稀释股数 | 0.00B | 0.00B | 0.01B | 0.00B | 0.00B | 0.00B |
| 现金流 | ||||||
| 经营现金流 | −$0.3M | −$10.7M | −$5.8M | −$5.8M | −$8.3M | −$4.2M |
| 资本支出 | $0.0M | $0.0M | $0.2M | $0.0M | $0.0M | $0.0M |
| 自由现金流 | −$0.3M | −$10.7M | −$6.0M | −$5.8M | −$8.3M | −$4.2M |
| 折旧与摊销 | $0.0M | $0.0M | $0.0M | $2.1M | $2.3M | $1.7M |
| 股权激励 | $0.1M | $0.6M | $0.7M | $0.5M | $0.2M | $0.0M |
| 资产负债表 | ||||||
| 现金及短期投资 | $0.7M | $27.7M | $15.3M | $5.0M | $1.9M | $6.9M |
| 总债务 | — | $3.4M | — | — | — | — |
| 流动资产 | $3.5M | $32.9M | $19.7M | $8.2M | $3.6M | $7.0M |
| 流动负债 | $22.1M | $2.5M | $4.3M | $6.0M | $5.8M | $6.2M |
| 存货 | — | — | — | — | $0.0M | — |
| 固定资产净额 | $0.1M | $0.0M | $0.2M | $0.1M | $0.1M | $0.0M |
| 总资产 | $6.2M | $35.7M | $24.6M | $15.8M | $9.4M | $9.5M |
| 总负债 | $22.3M | $5.9M | $4.3M | $6.1M | $6.0M | $6.4M |
| 股东权益 | −$27.3M | $29.8M | $20.3M | $9.7M | $3.3M | $3.1M |
| 利润率 | ||||||
| 毛利率 | 56.2% | 52.9% | 54.3% | 51.9% | 45.0% | 11.2% |
| 营业利润率 | −29.4% | −53.2% | −97.9% | −112.5% | −137.0% | −465.4% |
| EBITDA 利润率 | −28.9% | −52.8% | −97.7% | −91.2% | −112.3% | −375.7% |
| 净利率 | −56.8% | −80.5% | −98.5% | −111.8% | −134.5% | −543.7% |
| 自由现金流利润率 | −3.5% | −95.8% | −58.0% | −58.7% | −89.3% | −219.9% |
| 回报率 | ||||||
| 资本回报率 | — | −85.5% | — | — | — | — |
| 已动用资本回报率 | 15.1% | −17.8% | −50.1% | −114.3% | −355.6% | −272.0% |
| 股本回报率 | — | −713.1% | −40.9% | −73.9% | −191.5% | −327.8% |
| 资产回报率 | −74.9% | −42.7% | −34.0% | −54.9% | −99.3% | −111.1% |
| 有形股本回报率 | — | −30.1% | −50.4% | −113.9% | −377.5% | −339.6% |
| 增长 | ||||||
| 营收增长 | — | 36.1% | −6.6% | −4.6% | −6.4% | −79.2% |
| 股数变化 | — | 358.0% | 106.3% | −94.9% | 57.2% | 547.4% |
| 财务健康 | ||||||
| 债务 / 股东权益 | — | 0.1x | — | — | — | — |
| 利息保障倍数 | −1.1x | −2.8x | −42.6x | −698.1x | −73.2x | −4,725.2x |
| 流动比率 | 0.2x | 13.2x | 4.6x | 1.4x | 0.6x | 1.1x |
| 速动比率 | 0.2x | 13.2x | 4.6x | 1.4x | 0.6x | 1.1x |
| 资本配置 | ||||||
| 资本支出 / 营收 | 0.0% | 0.0% | 2.1% | 0.2% | 0.3% | 0.0% |
| 股权激励 / 营收 | 1.1% | 5.6% | 6.5% | 4.6% | 2.7% | 1.1% |
| 质量评分 | ||||||
| Piotroski F 分数 | — | 2.0 | 3.0 | 3.0 | 2.0 | 3.0 |
| Altman Z'' | −38.9 | 6.3 | −0.1 | −14.4 | −35.2 | −33.5 |
| 应计比率 | −70.3% | 8.1% | −14.7% | −26.2% | −33.6% | −66.2% |
来源:SEC EDGAR XBRL 文件 (CIK 0001558569). 数据更新于 2026年10月24日。 第四季度数据为全年减去前九个月。 仅供参考,不构成投资建议。依赖任何数字前,请核对原始文件。
